中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

83 records (took 0.024 seconds)

    MULTIVALENT ANTIBODIES
    2.
    发明申请
    MULTIVALENT ANTIBODIES 审中-公开
    多功能抗体

    公开(公告)号：WO2011061492A2

    公开(公告)日：2011-05-26

    申请号：PCT/GB2010002120

    申请日：2010-11-17

    Applicant: UCB PHARMA SA ,  HUMPHREYS DAVID PAUL ,  HEYWOOD SAM PHILIP ,  LAWSON ALASTAIR DAVID GRIFFITHS

    Inventor： HUMPHREYS DAVID PAUL ,  HEYWOOD SAM PHILIP ,  LAWSON ALASTAIR DAVID GRIFFITHS

    IPC: C07K16/00

    CPC classification number: C07K16/00 ,  A61K47/60 ,  C07K2317/522 ,  C07K2317/55 ,  C07K2317/60 ,  C07K2317/624

    Abstract: A multivalent antibody fusion protein comprising: a heavy chain comprising, in sequence from the N-terminal, a variable domain nominally VH1, a CH1 region and a further variable domain nominally VH2, a light chain comprising, in sequence from the N-terminal, a variable domain nominally VL1, a CL domain and a variable domain nominally VL2, wherein said heavy and light chains are aligned to provide a first binding site formed by a first variable domain pair of VH1 and VL1 and a second binding site formed by a second variable domain pair of VH2 and VL2, wherein there is a disulfide bond between a variable domain pair forming a binding site, and said fusion protein is conjugated to a PEG polymer.

    Abstract translation: 一种多价抗体融合蛋白，其包含：重链，其从N末端依次包含名义上为VH1的可变结构域，CH1区域和名义上为VH2的另外的可变区，轻链，其从N末端依次包含， 可变结构域名义上为VL1，CL结构域和名义上为VL2的可变结构域，其中所述重链和轻链对齐以提供由第一可变结构域对VH1和VL1形成的第一结合位点和由第二结合位点形成的第二结合位点 VH2和VL2的可变结构域对，其中在形成结合位点的可变结构域对之间存在二硫键，并且所述融合蛋白与PEG聚合物缀合。

    MULTIVALENT ANTIBODIES
    3.
    发明申请
    MULTIVALENT ANTIBODIES 审中-公开
    多抗体

    公开(公告)号：WO2011061246A2

    公开(公告)日：2011-05-26

    申请号：PCT/EP2010067731

    申请日：2010-11-18

    Applicant: UCB PHARMA SA ,  HEYWOOD SAM PHILIP ,  HUMPHREYS DAVID PAUL ,  LAWSON ALASTAIR DAVID GRIFFITHS

    Inventor： HEYWOOD SAM PHILIP ,  HUMPHREYS DAVID PAUL ,  LAWSON ALASTAIR DAVID GRIFFITHS

    IPC: C07K16/00

    CPC classification number: C07K16/00 ,  C07K2317/35 ,  C07K2319/30 ,  C07K2319/31

    Abstract: A multivalent antibody fusion protein comprising: a heavy chain comprising, in sequence from the N-terminal, a variable domain nominally VH1, a CH1 region and a further variable domain nominally VH2, a light chain comprising, in sequence from the N-terminal, a variable domain nominally VL1, a CL domain and a variable domain nominally VL2, wherein said heavy and light chains are aligned to provide a first binding site formed by a first variable domain pair of VH1 and VL1 and a second binding site formed by a second variable domain pair of VH2 and VL2, and said fusion protein is conjugated to a PEG polymer.

    Abstract translation: 一种多价抗体融合蛋白，其包含：重链，其从N-末端开始依次包含可变结构域名义上的VH1，CH1区和另外的可变结构域名义上的VH2，轻链依次包含N-末端， 可变结构域名义上为VL1，CL结构域和名义上可变域为VL2，其中所述重链和轻链对齐以提供由VH1和VL1的第一可变结构域对形成的第一结合位点和由第二可变结构域形成的第二结合位点 VH2和VL2的可变结构域对，并且所述融合蛋白与PEG聚合物缀合。

    ANTIBODY-GUIDED FRAGMENT GROWTH
    4.
    发明申请
    ANTIBODY-GUIDED FRAGMENT GROWTH 审中-公开
    抗体引导片段增长

    公开(公告)号：WO2010079345A3

    公开(公告)日：2010-11-25

    申请号：PCT/GB2010000040

    申请日：2010-01-12

    Applicant: UCB PHARMA SA ,  LAWSON ALASTAIR DAVID GRIFFITHS

    Inventor： LAWSON ALASTAIR DAVID GRIFFITHS

    IPC: G01N33/68

    CPC classification number: C07K16/24 ,  C07K2299/00 ,  C07K2317/55 ,  C07K2317/76 ,  G01N33/6803 ,  G01N2500/04 ,  G06F19/16 ,  G06F19/70

    Abstract: The present invention relates to an improved method for drug discovery comprising using contact residue information derived from antibody-protein target interactions to help to direct the growth of small molecule fragments during the synthesis of a drug candidate. In particular, the present invention relates to the use of atomic structural information derived from antibody-protein interactions to guide the growth of small molecular fragments during lead optimisation, thus generating small molecule compounds which can alter the biological activity of a target protein.

    Abstract translation: 本发明涉及用于药物发现的改进方法，其包括使用衍生自抗体 - 蛋白质靶相互作用的接触残基信息来帮助在合成候选药物期间引导小分子片段的生长。 特别地，本发明涉及从抗体 - 蛋白质相互作用衍生的原子结构信息在铅优化过程中引导小分子片段的生长，从而产生可改变靶蛋白的生物活性的小分子化合物。

Patent Agency Ranking